PATHFINDER 2 is the largest study of the Galleri test so far, covering nearly 36,000 adults aged 50 and over across the US and Canada who had no suspicion of cancer. Published in a leading oncology journal, it reports how well the test performs in the kind of everyday population it’s designed for — including how often it correctly flags a signal and predicts where the cancer is.
Source: McDonnell CH, et al. PATHFINDER 2 registrational study. J Clin Oncol. 2026;44(17_suppl):LBA10509
A US study in over 6,600 adults over 50. When the Galleri® test flagged a signal, it pointed to the right place 97% of the time.
The NHS-Galleri trial followed over 140,000 people. Its main goal wasn't met — but the most advanced, stage IV diagnoses fell
A follow-up asked how people coped emotionally with cancer blood testing. Most reported little distress, and those who got a signal returned to normal within a year.